HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $9
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $9
HC Wainwright& Co.維持對世紀治療的買入評級,將目標價降至9美元。
HC Wainwright & Co. analyst Mitchell Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $11 to $9.
HC Wainwright & Co.分析師米切爾·卡普爾(Mitchell Kapoor)維持對世紀幹細胞(納斯達克:IPSC)的買入評級,並將目標股價從$11下調至$9。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。